Session 3: Medical & Pediatric Oncology and Clinical Trials

Chair(s)

• 

  Mark Dickson, MD

  Associate Attending Physician
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States

Moderator(s)

• AZ

  Alona Zer, MD
• 

  Albiruni Ryan Abdul Razak, MB, MRCPI (he/him/his)

  Staff Medical Oncologist, Solid Tumor Program and Medical Oncology Lead, Sarcoma Program
  Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto; Department of Medical Oncology, Mount Sinai Hospital
  Toronto, Ontario, Canada
• 

  Michael Wagner, MD (he/him/his)

  Associate Professor
  University of Washington/Fred Hutch Cancer Center
  Seattle, Washington, United States

Presentations:

• 1:00 PM – 1:08 PM

  A PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
  

  Author: Brian A. Van Tine, MD, PhD – Washington University School of Medicine

  Co-Author: Matthew A. Ingham, MD – New York Presbyterian Hospital/Columbia University Medical Center

  Co-Author: Steven Attia, D.O. – Mayo Clinic

  Co-Author: Christian F. Meyer, MD, PhD – Johns Hopkins Sidney Kimmel Cancer Center

  Co-Author: John D. Baird, PhD (he/him/his) – PTC Therapeutics, Inc.

  Co-Author: Dhiren D'Silva, MBA (he/him/his) – PTC Therapeutics, Inc.

  Co-Author: Kylie O’Keefe, n/a – PTC Therapeutics, Inc.

  Co-Author: Pius P. Maliakal, MS, PhD – PTC Therapeutics, Inc.

  Co-Author: Mona Wahba, MD, MSM – PTC Therapeutics, Inc.

  Co-Author: Marla Weetall, PhD – PTC Therapeutics, Inc.

  Co-Author: Gary K. Schwartz, MD – Columbia University Herbert Irving Comprehensive Cancer Center
• 1:08 PM – 1:16 PM

  PHASE II MULTI-CENTER TRIAL OF TRABECTEDIN IN COMBINATION WITH OLAPARIB IN ADVANCED UNRESECTABLE OR METASTATIC SARCOMA
  

  Author: Brittany L. Siontis, MD – Mayo Clinic

  Co-Author: Lili Zhao, PhD – University of Michigan

  Co-Author: Scott M. Schuetze, MD, PhD (he/him/his) – University of Michigan

  Co-Author: Amanda Fox, PA-C – University of Michigan

  Co-Author: Laurie Zyczynski, PA-C (she/her/hers) – University of Michigan

  Co-Author: Steven I. Robinson, MBBS – Mayo Clinic

  Co-Author: Scott Okuno, MD – Mayo Clinic

  Co-Author: Thanh P. Ho, MD – Mayo Clinic

  Co-Author: Rashmi Chugh, MD – University of Michigan
• 1:16 PM – 1:24 PM

  A PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 IN PATIENTS WITH SOLID TUMORS, INCLUDING ADVANCED/METASTATIC LIPOSARCOMA
  

  Author: Mrinal M. Gounder, MD – Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center

  Co-Author: Patrick Schöffski, MD, MPH – Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute

  Co-Author: Noboru Yamamoto, N/A, MD, PhD – Department of Experimental Therapeutics, National Cancer Center Hospital

  Co-Author: Todd M. Bauer, N/A, MD – Sarah Cannon Research Institute, Tennessee Oncology

  Co-Author: Manish R. Patel, N/A, MD – Sarah Cannon Research Institute, Florida Cancer Specialists & Research Institute

  Co-Author: Junxian Geng, PhD – Boehringer Ingelheim Pharmaceuticals, Inc.

  Co-Author: Sara Durland-Busbice, N/A, n/a – Boehringer Ingelheim Pharmaceuticals Inc

  Co-Author: Michael Teufel, PhD (he/him/his) – Boehringer Ingelheim Pharmaceuticals, Inc.

  Co-Author: Girish Jayadeva, N/A, MBBS, PhD – Boehringer Ingelheim International GmbH

  Co-Author: Patricia LoRusso, N/A, PhD – Yale University School of Medicine, Yale Cancer Center
• 1:24 PM – 1:32 PM

  SUSTAINED DISEASE CONTROL WITH MDM2 INHIBITOR MILADEMETAN IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA
  

  Author: Mrinal M. Gounder, MD – Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center

  Co-Author: Amy M. Weise, DO – Barbara Ann Karmanos Cancer Institute, Karmanos Cancer Institute

  Co-Author: Prasanna Kumar, PhD – Daiichi Sankyo, Inc.

  Co-Author: Ben Tao, MS – Daiichi Sankyo, Inc.

  Co-Author: Arnaud Lesegretain, MBA – Daiichi Sankyo, Inc.

  Co-Author: Vijaya G. Tirunagaru, PhD – Rain Therapeutics, Inc.

  Co-Author: Feng Xu, MS (he/him/his) – Rain Therapeutics, Inc.

  Co-Author: Richard Bryce, MBChB, MRCGP, MFPM – Rain Therapeutics, Inc.

  Co-Author: David S. Hong, MD – The University of Texas MD Anderson Cancer Center
• 1:32 PM – 1:40 PM

  Q&A
• 1:40 PM – 1:48 PM

  SARC031: A PHASE 2 TRIAL OF SELUMETINIB AND SIROLIMUS FOR PATIENTS WITH UNRESECTABLE OR METASTATIC MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
  

  Author: AeRang Kim, MD, PhD – Children's National Hospital

  Co-Author: Karla V. Ballman, PhD – Weill Cornell

  Co-Author: Pamela Wolters, PhD – National Cancer Institute

  Co-Author: Rachel Heise, n/a – Weill Cornell Medicine

  Co-Author: John F. Shern, MD – Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute

  Co-Author: Taylor Sundby, MD – National Cancer Institute

  Co-Author: Jane Trepel, n/a – National Cancer Institute

  Co-Author: Angela C. Hirbe, MD, PhD (she/her/hers) – Washington University in St. Louis

  Co-Author: Brian A. Van Tine, MD, PhD – Washington University School of Medicine

  Co-Author: Christian F. Meyer, MD, PhD – Johns Hopkins Sidney Kimmel Cancer Center

  Co-Author: Natalie B. Collins, MD, PhD (she/her/hers) – Dana Farber Cancer Institute

  Co-Author: Denise Reinke, NP, MBA – University of Michigan Comprehensive Cancer Center

  Co-Author: Karen Cichowski, PhD – Brigham and Women's Hospital

  Co-Author: Brigitte C. Widemann, MD – National Cancer Institute
• 1:48 PM – 1:56 PM

  P10015/SARC033: A PHASE 2 TRIAL OF TRAMETINIB IN PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA
  

  Author: Scott M. Schuetze, MD, PhD (he/him/his) – University of Michigan

  Co-Author: Karla V. Ballman, PhD – Weill Cornell

  Co-Author: Kristen N. Ganjoo, MD – Stanford Cancer Center, Stanford University

  Co-Author: Elizabeth J. Davis, MD – Vanderbilt University Medical Center

  Co-Author: Gabriel Tinoco, MD – The Ohio State University Comprehensive Cancer Center

  Co-Author: Melissa Burgess, N/A, M.D. – University of Pittsburgh

  Co-Author: Brian A. Van Tine, MD, PhD – Washington University School of Medicine

  Co-Author: Edwin Choy, MD, PhD (he/him/his) – Massachusetts General Hospital

  Co-Author: Dale R. Shepard, MD, PhD – Cleveland Clinic Taussig Cancer Institute

  Co-Author: Jeffrey A. Morgan, N/A, MD – Dana-Farber Cancer Institute

  Co-Author: Ciara M. Kelly, MD – Memorial Sloan Kettering Cancer Center

  Co-Author: Richard F. Riedel, MD – Duke Cancer Institute, Duke University Medical Center

  Co-Author: Margaret von Mehren, MD (she/her/hers) – Fox Chase Cancer Center

  Co-Author: Brittany L. Siontis, MD – Mayo Clinic

  Co-Author: Steven Attia, D.O. – Mayo Clinic

  Co-Author: Gary K. Schwartz, MD – Columbia University Herbert Irving Comprehensive Cancer Center

  Co-Author: Hari Deshpande, MD (he/him/his) – Yale

  Co-Author: Erin Kozlowski, MSA – SARC

  Co-Author: Helen X. Chen, N/A, M.D. – National Cancer Institute

  Co-Author: Brian P. Rubin, MD, PhD – Cleveland Clinic
• 1:56 PM – 2:00 PM

  Q&A
• 2:00 PM – 2:08 PM

  UPDATED EFFICACY AND SAFETY OF ENTRECTINIB IN PATIENTS WITH NTRK FUSION-POSITIVE SARCOMAS
  

  Author: Herbert H. Loong, MBBS, PDipMDPath, MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine) – The Chinese University of Hong Kong

  Co-Author: Laura Medina Rodríguez, MD (she/her/hers) – Unidad de Gestión Clínica Intercentros de Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria. Málaga.

  Co-Author: Gabriel Tinoco, MD – The Ohio State University Comprehensive Cancer Center

  Co-Author: Ignacio Garrido-Laguna, N/A, MD, PhD – Huntsman Cancer Institute at the University of Utah

  Co-Author: Koichi Goto, N/A, MD – National Cancer Center Hospital East

  Co-Author: Conor Steuer, N/A, MD – Winship Cancer Institute, Emory University School of Medicine

  Co-Author: Stephen V Liu, N/A, MD – Georgetown University Medical Center

  Co-Author: Stuart Osborne, N/A, MSc – F. Hoffmann-La Roche Ltd

  Co-Author: Walter Bordogna, N/A, PhD – F. Hoffmann-La Roche Ltd

  Co-Author: Sebastian Heinzmann, N/A, PhD – F. Hoffmann-La Roche Ltd

  Co-Author: Harald Zeuner – F. Hoffmann-La Roche Ltd

  Co-Author: George D. Demetri, MD (he/him/his) – Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School
• 2:08 PM – 2:16 PM

  LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE FUSION SARCOMAS
  

  Author: Catherine M. Albert, MD – Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center

  Co-Author: Daniel Orbach, MD (he/him/his) – SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Institut Curie and Paris Sciences et Lettres

  Co-Author: Christian Michel Zwaan, MD, PhD – Prinses Maxima Centrum

  Co-Author: Birgit Geoerger, MD, PhD – Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, INSERM U1015

  Co-Author: Claudia Blattmann, MD – Olgahospital

  Co-Author: Steven G. DuBois, MD (he/him/his) – Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

  Co-Author: Noah Federman, MD (he/him/his) – David Geffen School of Medicine, UCLA Jonsson Comprehensive Cancer Center

  Co-Author: Leo Mascarenhas, MD, MS (he/him/his) – Children's Hospital Los Angeles, University of Southern California Keck School of Medicine

  Co-Author: Ramamoorthy Nagasubramanian, MD – Nemours Children's Hospital

  Co-Author: Tanya C. Watt, MD – University of Texas Southwestern Medical Center

  Co-Author: Ricarda Norenberg, MS – Chrestos Concept GmbH & Co. KG

  Co-Author: Pierre Arvis, MD – Bayer Pharmaceuticals

  Co-Author: Esther De La Cuesta, MD, MBA (she/her/hers) – Bayer HealthCare Pharmaceuticals, Inc.

  Co-Author: Theodore W. Laetsch, MD – The Children’s Hospital of Philadelphia, University of Pennsylvania

  Co-Author: Cornelis M. Van Tilburg, MD, PhD – Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ)

  Co-Author: Rui-Hua Xu, MD, PhD – Sun Yat-sen University Cancer Center
• 2:16 PM – 2:24 PM

  DISCONTINUATION OF LAROTRECTINIB PRIOR TO DISEASE PROGRESSION IN PEDIATRIC SARCOMA: UPDATED ANALYSIS FROM SCOUT TRIAL
  

  Author: Theodore W. Laetsch, MD – The Children’s Hospital of Philadelphia, University of Pennsylvania

  Co-Author: Steven G. DuBois, MD (he/him/his) – Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

  Co-Author: Noah Federman, MD (he/him/his) – David Geffen School of Medicine, UCLA Jonsson Comprehensive Cancer Center

  Co-Author: Catherine M. Albert, MD – Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center

  Co-Author: Christian Michel Zwaan, MD, PhD – Prinses Maxima Centrum

  Co-Author: Lorena Valero-Arrese, MD – Hospital Universitari Vall d'Hebron

  Co-Author: Claudia Blattmann, MD – Olgahospital

  Co-Author: Birgit Geoerger, MD, PhD – Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, INSERM U1015

  Co-Author: Alberto Pappo, MD – Department of Oncology, St. Jude Children's Research Hospital

  Co-Author: Sébastien Perreault, MD (he/him/his) – Department of Neurosciences, CHU Sainte Justine

  Co-Author: Neerav Shukla, MD – Department of Pediatrics, Memorial Sloan Kettering Cancer Center

  Co-Author: Ricarda Norenberg, MS – Chrestos Concept GmbH & Co. KG

  Co-Author: Laura Dima, MD – Bayer HealthCare SAS, Medical Affairs

  Co-Author: Esther De La Cuesta, MD, MBA (she/her/hers) – Bayer HealthCare Pharmaceuticals, Inc.

  Co-Author: Daniel Orbach, MD (he/him/his) – SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Institut Curie and Paris Sciences et Lettres

  Co-Author: Cornelis M. Van Tilburg, MD, PhD – Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ)

  Co-Author: Leo Mascarenhas, MD, MS (he/him/his) – Children's Hospital Los Angeles, University of Southern California Keck School of Medicine
• 2:24 PM – 2:30 PM

  Q&A